Copyright 2009 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2009
We herein describe a new clinical finding of leukonychia occurring in 3 patients with mycosis fungoides (MF) being treated with vorinostat (Zolinza; Merck & Co Inc, Whitehouse Station, New Jersey), a zinc-dependent histone deacetylase (HDAC) inhibitor approved for the treatment of cutaneous T-cell lymphoma.1
Patient 1 was a 70-year-old white woman with stage IVA MF treated previously with methotrexate, interferon alfa, bexarotene, topical nitrogen mustard, and psoralen–UV-A therapy (PUVA). She had been taking vorinostat, 300 to 400 mg/d, for 6 months when diffuse leukonychia of the fingernails was noted (Figure 1). Vorinostat treatment was discontinued after 10 months owing to persistent disease, and by 10 months later, her nails had returned to normal.
Anderson KA, Bartell HL, Olsen EA. Leukonychia Related to Vorinostat. Arch Dermatol. 2009;145(11):1338-1339. doi:10.1001/archdermatol.2009.272